0A5J Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.38 |
| 52 Week High | €42.20 |
| 52 Week Low | €30.15 |
| Beta | 1.15 |
| 1 Month Change | 5.49% |
| 3 Month Change | 9.32% |
| 1 Year Change | 22.79% |
| 3 Year Change | -33.70% |
| 5 Year Change | n/a |
| Change since IPO | -17.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A5J | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 13.3% | -2.0% | 0.2% |
| 1Y | 22.8% | 6.0% | 6.3% |
Return vs Industry: 0A5J exceeded the UK Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: 0A5J exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| 0A5J volatility | |
|---|---|
| 0A5J Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A5J has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A5J's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| 0A5J fundamental statistics | |
|---|---|
| Market cap | €2.23b |
| Earnings (TTM) | €90.59m |
| Revenue (TTM) | €1.17b |
24.6x
P/E Ratio1.9x
P/S RatioIs 0A5J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A5J income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €439.61m |
| Gross Profit | €734.32m |
| Other Expenses | €643.74m |
| Earnings | €90.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 62.55% |
| Net Profit Margin | 7.72% |
| Debt/Equity Ratio | 174.1% |
How did 0A5J perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield52%
Payout RatioDoes 0A5J pay a reliable dividends?
See 0A5J dividend history and benchmarks| Dermapharm Holding dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2025 |
| Dividend Pay Date | Jul 01 2025 |
| Days until Ex dividend | 95 days |
| Days until Dividend pay date | 99 days |
Does 0A5J pay a reliable dividends?
See 0A5J dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 02:33 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dermapharm Holding SE is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Daniel Wendorff | Commerzbank AG |
| Fabian Piasta | Jefferies LLC |